Verrica Pharmaceuticals Set to Discuss Q4 and Full-Year 2023 Financial Results in Upcoming Conference Call

Verrica Pharmaceuticals Inc

WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), a trailblazing company in the field of dermatology therapeutics, has announced it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, February 29, 2024. The purpose of the call is to provide an update on the company’s progress and discuss its financial results for the fourth quarter and full year ended December 31, 2023.

Those interested in participating in the live call can do so by dialing 1-877-407-4018 if they’re calling from within the U.S., or 1-201-689-8471 for international callers. The conference ID to access the call is 13744217. Participants are requested to dial in 10 minutes prior to the call’s start time to register.

For those who prefer a more visual approach, a live audio webcast of the call will be available. This can be accessed by visiting the investor relations section of Verrica’s website. A replay of the webcast will also be archived on the company’s website, making it accessible for 90 days following the event.

Based in West Chester, Pennsylvania, Verrica Pharmaceuticals has made a name for itself by developing treatments for skin diseases that require medical interventions. The company achieved a significant milestone on July 21, 2023, when the FDA approved its lead product, YCANTH (cantharidin), as the first treatment for adult and pediatric patients aged two years and older with molluscum contagiosum. This viral skin infection, which is highly contagious, affects approximately 6 million people in the U.S., primarily children.

Verrica is not resting on its laurels, however. The company is currently developing VP-102 to treat common warts and external genital warts, two of the most significant unmet needs in medical dermatology since YCANTH’s approval. Additionally, the company is working on VP-103, a second cantharidin-based product candidate, for the treatment of plantar warts.

READ:  Verrica Pharmaceuticals Reports Q3 2024 Financials and Restructuring Plans

The company has also entered into a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315, previously known as LTX-315 and VP-LTX-315, for non-melanoma skin cancers, including basal cell carcinoma.

This upcoming conference call will provide an exciting opportunity for industry watchers to gain insight into Verrica’s latest developments and financial performance, offering a glimpse into the future direction of this innovative pharmaceutical company.

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.